Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR5A2 | O00482 | 1/20 | 0.32 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 3/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | TYR | P14679 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7519511 | 0.99 | NR5A2 (0.32) | NR5A2NR5A1CA2CA1ALDH1A1 | |
| SCHEMBL7525491 | 0.99 | NR5A2 (0.32) | NR5A2NR5A1CA2CA1ALDH1A1 | |
| SCHEMBL7520082 | 0.99 | NR5A2 (0.32) | NR5A2NR5A1CA2CA1ALDH1A1 | |
| SCHEMBL7521635 | 0.96 | NR5A2 (0.33) | NR5A2NR5A1CA2CA1ALDH1A1 | |
| SCHEMBL7523511 | 0.92 | CA2 (0.33) | CA2CA1ALDH1A1KDM4EMAPT | |
| SCHEMBL7524824 | 0.88 | CA2 (0.33) | CA2CA1ALDH1A1KDM4EMAPT | |
| SCHEMBL7527616 | 0.85 | — | — | |
| SCHEMBL7525761 | 0.79 | GAA (0.35) | ALDH1A1PTGS2 | |
| SCHEMBL6308900 | 0.77 | CA2 (0.40) | CA2CA1ALDH1A1KDM4EMAPT | |
| SCHEMBL6306885 | 0.76 | ALDH1A1 (0.33) | CA2CA1ALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6103753-A | ADMINISTERING TO A PATIENT FOR INHIBITING THICKENING OF VASCULAR STENOSIS FOLLOWING PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY, A 2,6-DI-T-BUTYLPHENOL DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-08-15 | — | — | US | claimed |
| EP-0868913-A1 | INTIMAL THICKENING INHIBITOR | Chugai Seiyaku Kabushiki Kaisha (JP) | 1998-10-07 | — | — | EP | claimed |
| JP-7330759-A | — | — | None | — | — | JP | disclosed |
| US-20050159476-A1 | Pharmaceutical composition for preventing or treating respiratory disease | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-07-21 | — | — | US | disclosed |
| EP-1490048-A4 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESPIRATORY DISEASE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-1490048-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESPIRATORY DISEASE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003082264-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESPIRATORY DISEASE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-10-09 | — | — | WO | disclosed |
| US-6440999-B1 | Intimal thickening inhibitory agent | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-08-27 | — | — | US | disclosed |
| EP-0791589-B1 | 4,6-DI-t-BUTYL-2,3-DIHYDROBENZOTHIOPHENES WHICH INHIBIT LDL OXIDATION | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2002-03-06 | — | — | EP | disclosed |
| US-6133279-A | A 2,6-DI-T-BUTYLPHENOL DERIVATIVE FOR RENAL DISEASES, E.G., CHRONIC RENAL FAILURE, DIABETIC NEPHROPATHY GLOMERULAR NEPHRITIS, IMMUNOCOMPLEX NEPHRITIS AND ACUTE RENAL FAILURE; CYTOPROTECTIVE AGENT THAT INHIBITS THE LIPID PEROXIDATION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-10-17 | — | — | US | disclosed |
| US-6103753-A | ADMINISTERING TO A PATIENT FOR INHIBITING THICKENING OF VASCULAR STENOSIS FOLLOWING PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY, A 2,6-DI-T-BUTYLPHENOL DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-08-15 | — | — | US | disclosed |
| EP-0950405-A1 | REMEDIES FOR RENAL DISEASES AND ORGAN-PRESERVING AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1999-10-20 | — | — | EP | disclosed |
| EP-0868913-A1 | INTIMAL THICKENING INHIBITOR | Chugai Seiyaku Kabushiki Kaisha (JP) | 1998-10-07 | — | — | EP | disclosed |
| US-5789436-A | ARTERIOSCLEROSIS; INHIBITORS OF OXIDATION OF LOW DENSITY LIPOPROTEINS; | CHUGAI SEIYAK KABUSHIKI KAISHA (JP) | 1998-08-04 | — | — | US | disclosed |
| EP-0791589-A1 | 4,6-DI-t-BUTYL-2,3-DIHYDROBENZOTHIOPHENES WHICH INHIBIT LDL OXIDATION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1997-08-27 | — | — | EP | disclosed |
| JP-H07330759-A | 4,6-DI-TERT-BUTYL-2,3-DIHYDROBENZOTHIOPHENE DERIVATIVE | CHUGAI PHARMACEUT CO LTD | 1995-12-19 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159476-A1 | Pharmaceutical composition for preventing or treating respiratory disease | CFTR, CMA1, SLC5A1 | NR5A2 711/4885NR5A1 16/4885CA2 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.